Stanley Laman Group Ltd. Has $5.76 Million Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Stanley Laman Group Ltd. raised its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 12.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 42,158 shares of the company’s stock after buying an additional 4,627 shares during the period. Neurocrine Biosciences accounts for 0.8% of Stanley Laman Group Ltd.’s holdings, making the stock its 26th largest holding. Stanley Laman Group Ltd.’s holdings in Neurocrine Biosciences were worth $5,755,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently added to or reduced their stakes in the company. Caprock Group LLC bought a new position in shares of Neurocrine Biosciences during the fourth quarter valued at $236,000. Plato Investment Management Ltd raised its stake in shares of Neurocrine Biosciences by 2,481.9% during the third quarter. Plato Investment Management Ltd now owns 10,973 shares of the company’s stock valued at $1,263,000 after acquiring an additional 10,548 shares during the last quarter. Swiss National Bank raised its stake in shares of Neurocrine Biosciences by 1.4% during the third quarter. Swiss National Bank now owns 298,700 shares of the company’s stock valued at $34,416,000 after acquiring an additional 4,100 shares during the last quarter. Tri Ri Asset Management Corp bought a new position in shares of Neurocrine Biosciences during the third quarter valued at $3,236,000. Finally, KBC Group NV raised its stake in shares of Neurocrine Biosciences by 78.3% during the third quarter. KBC Group NV now owns 18,972 shares of the company’s stock valued at $2,186,000 after acquiring an additional 8,332 shares during the last quarter. Institutional investors and hedge funds own 92.59% of the company’s stock.

Insider Buying and Selling

In other Neurocrine Biosciences news, insider Julie Cooke sold 700 shares of the business’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $118.28, for a total value of $82,796.00. Following the transaction, the insider now directly owns 18,831 shares in the company, valued at $2,227,330.68. The trade was a 3.58 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Kyle Gano sold 65,000 shares of the business’s stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $141.50, for a total transaction of $9,197,500.00. Following the completion of the transaction, the chief executive officer now owns 135,392 shares in the company, valued at approximately $19,157,968. The trade was a 32.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 226,647 shares of company stock worth $33,186,271. 4.30% of the stock is owned by insiders.

Neurocrine Biosciences Price Performance

Shares of NASDAQ NBIX opened at $117.18 on Thursday. The stock has a market capitalization of $11.86 billion, a P/E ratio of 35.62 and a beta of 0.33. The company has a 50-day moving average price of $138.49 and a 200-day moving average price of $131.02. Neurocrine Biosciences, Inc. has a 1 year low of $110.95 and a 1 year high of $157.98.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings results on Thursday, February 6th. The company reported $1.00 earnings per share for the quarter, missing the consensus estimate of $1.62 by ($0.62). Neurocrine Biosciences had a return on equity of 13.45% and a net margin of 14.49%. As a group, equities research analysts anticipate that Neurocrine Biosciences, Inc. will post 6.53 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on NBIX. Wedbush dropped their price target on shares of Neurocrine Biosciences from $157.00 to $147.00 and set an “outperform” rating for the company in a research note on Friday, February 7th. Barclays lifted their target price on shares of Neurocrine Biosciences from $160.00 to $165.00 and gave the stock an “overweight” rating in a research note on Monday, December 23rd. Royal Bank of Canada lowered their target price on shares of Neurocrine Biosciences from $154.00 to $148.00 and set a “sector perform” rating for the company in a research note on Friday, February 7th. Morgan Stanley lifted their target price on shares of Neurocrine Biosciences from $170.00 to $185.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 4th. Finally, StockNews.com raised shares of Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research note on Monday. Five equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $166.90.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.